

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed for Go Clear

Limits

Preview/Index

History

Clipboard

Details

Display Abstract Show 20 Sort by Send to

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Arch Dermatol. 1996 Oct;132(10):1207-11.

Related Articles, Links

Keratinocytes as a target for gene therapy. Sustained production of erythropoietin in mice by human keratinocytes transduced with an adenoassociated virus vector.**Descamps V, Blumenfeld N, Beuzard Y, Perricaudet M.**

Department of Dermatology, Hopital Bichat, Paris, France.




BACKGROUND AND DESIGN: Keratinocytes are ideal targets for somatic gene therapy. Among the viral gene transfer systems, adenoassociated virus vectors have recently gained attention. We studied the feasibility of using adenoassociated virus-transduced human keratinocytes to provide a long-term, high-level production of a therapeutic factor after implantation in mice. **RESULTS:** Transduction of HeLa cells by an adenoassociated virus vector was ascertained by transfer of the beta-galactosidase reporter gene, which was visualized by the blue staining of infected cells after fixation and coloring by X-Gal (the substrate of the reaction for beta-galactosidase activity). In a second step, 2 HeLa cell lines transduced with an AAV harboring the erythropoietin complementary DNA and producing high amounts of erythropoietin in vitro were isolated. After implantation in nude mice, a high-level and long-term increase in hematocrit (for the 1-month duration of the study) was found, which was correlated to the size of the induced tumor. **CONCLUSIONS:** Adenoassociated virus-transduced HeLa keratinocytes provide high-level, stable, and long-term production of a therapeutic protein in mice. These results must now be extended to human primary keratinocytes.

PMID: 8859032 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)Search for [Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

[About Entrez](#)[Text Version](#)**Entrez PubMed**[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)**Search****Most Recent Queries****Time Result**

#1 Search descamps and keratinocytes and 1996

14:44:37 2

PubMed Services[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)**Related Resources**[Order Documents](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	11	530/395.ccls. and EPO and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/13 14:37
S1	122	530/395.ccls. and EPO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/09/07 07:24
S2	13	530/395.ccls. and EPO SAME CHO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/09/07 07:24
S3	1212	EPO SAME composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/12 00:06
S4	0	EPO SAME composition SAME glycosylated and "N-acetyl lactosamine" and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:12
S5	0	EPO SAME composition SAME glycosylated and "N-acetyl lactosamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:12
S6	40	EPO SAME composition SAME glycosylated	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:12
S7	1	EPO SAME composition SAME glycosylated and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:14
S8	1	EPO SAME composition SAME lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:15
S9	3	EPO SAME composition and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:17
S10	19	EPO and composition and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:17
S11	16	EPO and composition and glycosylated and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:17

S12	0	EPO.ab. and composition and glycosylated and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:17
S13	0	EPO.ti. and composition and glycosylated and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:17
S14	8	erythropoietin and composition and glycosylated and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:18
S15	16	EPO and composition and glycosylated and lactosamine and carbohydrate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:18
S16	93	EPO.ab. SAME composition.ab.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:19
S17	2	EPO.ab. and composition.ab. and glycosylated.ab.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:21
S18	1	EPO.ab. and EPO SAME composition SAME glycosylated	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:21
S19	125	EPO.ab. and EPO SAME composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:22
S20	0	EPO.ab. and EPO SAME composition and lactosamine SAME glycosylated	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:22
S21	2	EPO.ab. and EPO SAME composition and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:22
S22	35	EPO.ab. and EPO SAME composition and glycosylat\$3	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:23
S23	3	EPO.ab. and EPO SAME composition SAME glycosylat\$3	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:23

S24	35	EPO.ab. and EPO SAME composition and glycosylat\$3	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:23
S25	3	EPO.ti. and EPO SAME composition and glycosylat\$3	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/06/02 11:23
S26	2	"9635718".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/08/13 00:33
S27	5	"267678".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/08/13 00:37
S28	4	"9512684".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/08/13 00:55
S29	96	530/395.ccls. and EPO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/08/13 00:56
S30	0	530/395.ccls. and EPO and sialyated	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/08/13 00:59
S31	2	"5106954".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:19
S32	2	"6399333".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:19
S33	0	"6399333".pn. and glycosylation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:20
S34	0	"6399333".pn. and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:20
S35	21	EPO and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:22

S36	1	erythropoietin SAME lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:21
S37	0	"6399333".pn. and "high specific activity"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:22
S38	2	EPO SAME lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:22
S39	21	erythropoietin and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:24
S40	2	"5324663".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:24
S41	0	"5324663".pn. and EPO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:24
S42	1	"5324663".pn. and erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:24
S43	1	"5324663".pn. and erythropoietin and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/02 11:24
S44	1285	EPO SAME composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 16:47
S45	9	EPO SAME composition SAME CHO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:04
S46	175	EPO SAME CHO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:04
S47	7	EPO.clm. and CHO.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:05

S48	27	EPO.clm. and EPO SAME glycosylation and CHO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:05
S49	12	EPO.clm. and EPO SAME glycosylation SAME CHO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:13
S50	32	EPO SAME glycosylation SAME CHO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:17
S51	7	EPO SAME glycosylation SAME CHO and sialylation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:19
S52	2	"5459031".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/04 17:20
S53	2	"5459031".pn. and EPO	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/05 17:45
S54	1	"5459031".pn. and EPO and glucose	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2003/09/05 17:45
S55	432	EPO and N-acetyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:25
S56	4	EPO and N-acetyl ADJ lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:27
S57	4	EPO and "N-acetyl lactosamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:27
S58	2	EPO SAME "N-acetyl lactosamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:32
S59	2	EPO SAME "N-acetyl lactosamine" and "LacNac"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:33

S60	12	EPO and "N-acetyllactosamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:54
S61	3	EPO and "N-acetyllactosamine" and LacNac	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:42
S62	0	EPO and "N-acetyllactosamine". clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:47
S63	2	EPO and "N-acetyllactosamine".ab.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 14:47
S64	41	erythropoietin and "N-acetyllactosamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 15:04
S65	8	erythropoietin SAME "N-acetyllactosamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:08
S66	10	erythropoietin and LacNac	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 15:02
S67	8	erythropoietin and LacNac and N-glycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 15:02
S68	3	erythropoietin SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:26
S69	7	EPO SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:20
S70	1	EPO and tetraantennary SAME lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:20
S71	0	EPO and tetraantennary SAME N-acetyllactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:20

S72	0	EPO and tetraantennary SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:20
S73	5	EPO and tetraantennary SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:22
S74	1	EPO and tetraantennary SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:22
S75	5	EPO and tetraantennary SAME acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:23
S76	2	erythropoietin SAME tetraantennary and N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:23
S77	0	erythropoietin SAME tetraantennary and N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:23
S78	0	erythropoietin SAME tetraantennary and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:23
S79	1	530/395.ccls. and erythropoietin SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:26
S80	0	530/395.ccls. and erythropoietin and tetraantennary and N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/12 22:27
S81	0	EPO and enhance SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:28
S82	0	EPO and enhancing SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:28
S83	0	EPO and enhancing SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:28

S84	1	EPO and enhancing SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:28
S85	0	EPO and increase SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:28
S86	3	EPO and increase SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:32
S87	3	erythropoietin and increase SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:31
S88	0	EPO and increasing SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:32
S89	1	EPO and increasing SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:32
S90	0	EPO and increasing SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:32
S91	2	EPO and increase SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:33
S92	2	erythropoietin and increase SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:33
S93	0	erythropoietin and increasing SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:33
S94	0	increasing SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:33
S95	4	increase SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:37

S96	0	enhance SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:37
S97	0	enhancing SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:37
S98	0	enhancing SAME N-acetyllactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:37
S99	2	enhancing SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:38
S10 0	1	increase SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:39
S10 1	1	increasing SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:40
S10 2	1	tetraantennary SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:40
S10 3	106	EPO SAME "human cell"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:46
S10 4	106	EPO SAME "human cells"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:46
S10 5	0	EPO SAME "human cells" SAME tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:46
S10 6	0	EPO SAME "human cells" SAME N-acetyllactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:47
S10 7	1	EPO SAME "human cells" SAME N-acetyl-lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:48

S10 8	4	EPO SAME "human cells" SAME glycosylation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:49
S10 9	40	EPO SAME CHO SAME glycosylation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:49
S11 0	32	EPO SAME "CHO cells" SAME glycosylation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:49
S11 1	3	EPO SAME "CHO cells" SAME glycosylation SAME increasing	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:49
S11 2	4	EPO SAME "CHO cells" SAME glycosylation SAME increase	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:50
S11 3	238	EPO and increase SAME glycosylation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:50
S11 4	10	EPO and increase SAME glycosylation and tetraantennary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/04/17 09:50
S11 5	4	530/395.ccls. and EPO and lactosamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/13 14:37
S12 4	63	EPO SAME "HeLa"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/04/12 00:06